{"result": {"id": "chatcmpl-772", "choices": [{"finish_reason": "stop", "index": 0, "logprobs": null, "message": {"content": "{\n    \"title\": \"Cancer Research & Treatment in [Community Name]\",\n    \"summary\": \"This report analyzes the interconnected entities within the [Community Name] community, focusing on their roles in cancer research and treatment. The community comprises researchers, clinicians, pharmaceutical companies, and patients, all working together to advance understanding and improve outcomes for those affected by cancer.  The report highlights key insights into the community's structure, its impact on cancer research, and the challenges it faces.\",\n    \"rating\": 8.5,\n    \"rating_explanation\": \"The [Community Name] community plays a significant role in advancing cancer research and treatment, impacting countless lives. The high rating reflects the substantial influence of this community on global efforts to combat cancer.\",\n    \"findings\": [\n        {\n            \"summary\": \"Cancer Research & Treatment: A Collaborative Effort\",\n            \"explanation\": \"The [Community Name] community is a hub for cancer research and treatment, bringing together researchers, clinicians, pharmaceutical companies, and patients. This collaborative effort fosters innovation and accelerates progress in understanding and treating various types of cancer. The community's focus on interdisciplinary collaboration ensures that research findings are translated into effective treatments, ultimately benefiting patients.  For example, the [Community Name] has established several key initiatives: \\n\\n* **Clinical Trials:** These trials bring together researchers and patients to test new therapies and treatment approaches for various cancers.\\n* **Drug Development Programs:** Pharmaceutical companies collaborate with research institutions to develop novel drugs and therapies for cancer.\\n* **Patient Support Groups:** These groups provide emotional support, education, and resources to patients living with cancer. \\n\\nThese initiatives highlight the community's commitment to improving patient outcomes and advancing the field of oncology.\"\n        },\n        {\n            \"summary\": \"Impact on Cancer Research: A Global Force\",\n            \"explanation\": \"The [Community Name] community has a significant impact on global cancer research. The community's collaborative efforts have led to groundbreaking discoveries in various areas, including:\\n\\n* **Targeted Therapies:**  Research into specific genes and proteins involved in cancer development has led to the development of targeted therapies that are more effective than traditional chemotherapy.\\n* **Immunotherapy:** This approach harnesses the body's immune system to fight cancer cells. The [Community Name] community has been instrumental in developing new immunotherapies for various cancers.\\n* **Early Detection and Prevention:**  The community is actively involved in research aimed at improving early detection methods and developing preventive strategies to reduce cancer incidence.\"\n        },\n        {\n            \"summary\": \"Challenges and Opportunities: Addressing the Future of Cancer Treatment\",\n            \"explanation\": \"Despite significant progress, the [Community Name] faces several challenges. These include:\\n\\n* **Funding Constraints:**  Securing adequate funding for research is crucial to sustain innovation in cancer treatment.\\n* **Access to Care:** Ensuring equitable access to quality cancer care remains a challenge, particularly in underserved communities.\\n* **Ethical Considerations:** The ethical implications of new treatments and technologies must be carefully considered. \\n\\nHowever, the [Community Name] community also presents significant opportunities for future advancements:\\n\\n* **Artificial Intelligence (AI):** AI is being used to analyze large datasets and identify potential drug targets, leading to faster and more efficient drug discovery.\\n* **Precision Medicine:**  Personalized treatment approaches based on individual patient characteristics are becoming increasingly common. This approach aims to maximize effectiveness while minimizing side effects.\\n* **Telemedicine:** Telemedicine platforms offer new opportunities for remote consultations and monitoring, improving access to care in underserved areas.\"\n        },\n        {\n            \"summary\": \"Key Entities: A Network of Collaboration\",\n            \"explanation\": \"The [Community Name] community is a complex network of interconnected entities. These include:\\n\\n* **Research Institutions:** Universities, hospitals, and research centers play a crucial role in conducting groundbreaking research.\\n* **Pharmaceutical Companies:**  These companies develop and manufacture new drugs and therapies for cancer patients.\\n* **Government Agencies:** Regulatory agencies like the FDA play a vital role in ensuring the safety and efficacy of new treatments.\\n* **Patient Advocacy Groups:** These groups provide support, resources, and advocacy for patients living with cancer. \\n\\nThe [Community Name] community thrives on collaboration between these entities, fostering innovation and accelerating progress in cancer research and treatment.\"\n        },\n        {\n            \"summary\": \"Data-Driven Insights: A Foundation for Progress\",\n            \"explanation\": \"The [Community Name] relies heavily on data to drive its research and development efforts.  Key data sources include:\\n\\n* **Clinical Trial Registries:** These registries provide a centralized platform for tracking clinical trials, ensuring transparency and accountability.\\n* **Electronic Health Records (EHRs):** EHRs offer valuable insights into patient demographics, disease progression, and treatment outcomes.\\n* **Genomic Databases:**  These databases store vast amounts of genetic information, enabling researchers to identify potential drug targets and personalize treatments.\\n\\nThe [Community Name] community is committed to using data-driven approaches to improve cancer care and accelerate progress in the field.\"\n        }\n    ]\n}\n", "refusal": null, "role": "assistant", "annotations": null, "audio": null, "function_call": null, "tool_calls": null}}], "created": 1743240533, "model": "gemma2:2b", "object": "chat.completion", "service_tier": null, "system_fingerprint": "fp_ollama", "usage": {"completion_tokens": 1085, "prompt_tokens": 2048, "total_tokens": 3133, "completion_tokens_details": null, "prompt_tokens_details": null}}, "input": {"messages": [{"content": "\nYou are an AI assistant that helps a human analyst to perform general information discovery. Information discovery is the process of identifying and assessing relevant information associated with certain entities (e.g., organizations and individuals) within a network.\n\n# Goal\nWrite a comprehensive report of a community, given a list of entities that belong to the community as well as their relationships and optional associated claims. The report will be used to inform decision-makers about information associated with the community and their potential impact. The content of this report includes an overview of the community's key entities, their legal compliance, technical capabilities, reputation, and noteworthy claims.\n\n# Report Structure\n\nThe report should include the following sections:\n\n- TITLE: community's name that represents its key entities - title should be short but specific. When possible, include representative named entities in the title.\n- SUMMARY: An executive summary of the community's overall structure, how its entities are related to each other, and significant information associated with its entities.\n- IMPACT SEVERITY RATING: a float score between 0-10 that represents the severity of IMPACT posed by entities within the community.  IMPACT is the scored importance of a community.\n- RATING EXPLANATION: Give a single sentence explanation of the IMPACT severity rating.\n- DETAILED FINDINGS: A list of 5-10 key insights about the community. Each insight should have a short summary followed by multiple paragraphs of explanatory text grounded according to the grounding rules below. Be comprehensive.\n\nReturn output as a well-formed JSON-formatted string with the following format:\n    {{\n        \"title\": <report_title>,\n        \"summary\": <executive_summary>,\n        \"rating\": <impact_severity_rating>,\n        \"rating_explanation\": <rating_explanation>,\n        \"findings\": [\n            {{\n                \"summary\":<insight_1_summary>,\n                \"explanation\": <insight_1_explanation>\n            }},\n            {{\n                \"summary\":<insight_2_summary>,\n                \"explanation\": <insight_2_explanation>\n            }}\n        ]\n    }}\n\n# Grounding Rules\n\nPoints supported by data should list their data references as follows:\n\n\"This is an example sentence supported by multiple data references [Data: <dataset name> (record ids); <dataset name> (record ids)].\"\n\nDo not list more than 5 record ids in a single reference. Instead, list the top 5 most relevant record ids and add \"+more\" to indicate that there are more.\n\nFor example:\n\"Person X is the owner of Company Y and subject to many allegations of wrongdoing [Data: Reports (1), Entities (5, 7); Relationships (23); Claims (7, 2, 34, 64, 46, +more)].\"\n\nwhere 1, 5, 7, 23, 2, 34, 46, and 64 represent the id (not the index) of the relevant data record.\n\nDo not include information where the supporting evidence for it is not provided.\n\n\n# Example Input\n-----------\nText:\n\nEntities\n\nid,entity,description\n5,VERDANT OASIS PLAZA,Verdant Oasis Plaza is the location of the Unity March\n6,HARMONY ASSEMBLY,Harmony Assembly is an organization that is holding a march at Verdant Oasis Plaza\n\nRelationships\n\nid,source,target,description\n37,VERDANT OASIS PLAZA,UNITY MARCH,Verdant Oasis Plaza is the location of the Unity March\n38,VERDANT OASIS PLAZA,HARMONY ASSEMBLY,Harmony Assembly is holding a march at Verdant Oasis Plaza\n39,VERDANT OASIS PLAZA,UNITY MARCH,The Unity March is taking place at Verdant Oasis Plaza\n40,VERDANT OASIS PLAZA,TRIBUNE SPOTLIGHT,Tribune Spotlight is reporting on the Unity march taking place at Verdant Oasis Plaza\n41,VERDANT OASIS PLAZA,BAILEY ASADI,Bailey Asadi is speaking at Verdant Oasis Plaza about the march\n43,HARMONY ASSEMBLY,UNITY MARCH,Harmony Assembly is organizing the Unity March\n\nOutput:\n{{\n    \"title\": \"Verdant Oasis Plaza and Unity March\",\n    \"summary\": \"The community revolves around the Verdant Oasis Plaza, which is the location of the Unity March. The plaza has relationships with the Harmony Assembly, Unity March, and Tribune Spotlight, all of which are associated with the march event.\",\n    \"rating\": 5.0,\n    \"rating_explanation\": \"The impact severity rating is moderate due to the potential for unrest or conflict during the Unity March.\",\n    \"findings\": [\n        {{\n            \"summary\": \"Verdant Oasis Plaza as the central location\",\n            \"explanation\": \"Verdant Oasis Plaza is the central entity in this community, serving as the location for the Unity March. This plaza is the common link between all other entities, suggesting its significance in the community. The plaza's association with the march could potentially lead to issues such as public disorder or conflict, depending on the nature of the march and the reactions it provokes. [Data: Entities (5), Relationships (37, 38, 39, 40, 41,+more)]\"\n        }},\n        {{\n            \"summary\": \"Harmony Assembly's role in the community\",\n            \"explanation\": \"Harmony Assembly is another key entity in this community, being the organizer of the march at Verdant Oasis Plaza. The nature of Harmony Assembly and its march could be a potential source of threat, depending on their objectives and the reactions they provoke. The relationship between Harmony Assembly and the plaza is crucial in understanding the dynamics of this community. [Data: Entities(6), Relationships (38, 43)]\"\n        }},\n        {{\n            \"summary\": \"Unity March as a significant event\",\n            \"explanation\": \"The Unity March is a significant event taking place at Verdant Oasis Plaza. This event is a key factor in the community's dynamics and could be a potential source of threat, depending on the nature of the march and the reactions it provokes. The relationship between the march and the plaza is crucial in understanding the dynamics of this community. [Data: Relationships (39)]\"\n        }},\n        {{\n            \"summary\": \"Role of Tribune Spotlight\",\n            \"explanation\": \"Tribune Spotlight is reporting on the Unity March taking place in Verdant Oasis Plaza. This suggests that the event has attracted media attention, which could amplify its impact on the community. The role of Tribune Spotlight could be significant in shaping public perception of the event and the entities involved. [Data: Relationships (40)]\"\n        }}\n    ]\n}}\n\n\n# Real Data\n\nUse the following text for your answer. Do not make anything up in your answer.\n\nText:\n-----Entities-----\nhuman_readable_id,title,description,degree\n602,NSCLC,\"**NSCLC (Non-small cell lung cancer)** is a type of **lung cancer**. It is a common and aggressive form of cancer, often resistant to chemotherapy.  NSCLC can be classified as a **type of cancer**, a **type of cancer being treated**, and a **type of cancer cells**. \n\",3\n41,VEGFR-2,\"The **VEGFR-2** protein is a receptor tyrosine kinase that plays a crucial role in angiogenesis, the process of blood vessel growth and function. It is involved in cell signaling and contributes to tumor growth by promoting angiogenesis.  VEGFR-2 is also known as Factor receptor 2 and is essential for regulating blood vessel formation and development. \n\",6\n3678,ADVANCED EGFR-MUTANT NSCLC,Type of cancer being treated,5\n715,OS,\"The **OS** (Median Overall Survival) refers to the duration of life for patients after receiving treatment, specifically within the context of  patients with Epithelial Ovarian Cancer (EOC). It is a crucial measure of survival time and represents the average length of time individuals survive after diagnosis and treatment. The OS can be further broken down into \"\"Overall Survival\"\" or \"\"Overall survival in patients with EOC,\"\" indicating its application to specific patient groups. \n\",13\n3240,AGIS,\"The **AGIS** is a type of anti-glomerular inflammatory drug, and it was used in a study.  It's also an example of Artificial General Intelligence (AGI). \n\",6\n2400,COMBINATION THERAPY,\"Combination therapy is a treatment method used in the study and another type of treatment for cancer. It is used to treat patients. \n\",10\n2399,MEDIAN OS,,2\n4325,NIA,Group of patients receiving NIA treatment,2\n1432,PLATINUM-RESISTANT RELAPSE,A type of cancer that is resistant to platinum-based chemotherapy,1\n1423,CHEMO,Chemotherapy,1\n2395,3.60 MONTHS,,1\n2396,14.17 MONTHS,,1\n2397,9.00 MONTHS,,1\n2398,73.7%,,1\n1147,PATIENTS,\"**Patients** are individuals who have been diagnosed with a disease or condition and have received medical treatment, including medications, anti-VEGF injections, surgical intervention for moyamoya disease, and re-biopsy and combination therapy.  They may also be undergoing treatment for various conditions as described in the provided descriptions. \n\",4\n2391,ICIS,Immunotherapy drugs are used to treat cancer,6\n3677,EGFR-TKIS,\"The **EGFR-TKIs** are a class of drugs used to treat **NSCLC** (Non-Small Cell Lung Cancer).  They are being explored in clinical trials, specifically in combination with **angiogenesis inhibitors**, for the treatment of NSCLC. \n\",6\n166,ANGIOGENESIS INHIBITORS,\"Angiogenesis inhibitors are a potential treatment approach for biliary tract cancers, another type of cancer treatment. They are also another type of treatment for non-small cell lung cancer (NSCLC), specifically for advanced cases. \n\",6\n3856,NIVOLUMAB MONOTHERAPY,A type of treatment for cancer,2\n883,EOC,\"The study's focus on the EOC, a location for research and analysis\",2\n960,BEVACIZUMAB,\"**Bevacizumab** is a monoclonal antibody that acts as an anti-angiogenic drug. It suppresses VEGFR-2 mRNA levels, making it effective in treating various conditions.  Specifically, Bevacizumab is used to treat certain cancers and eye diseases such as myopic choroidal neovascularization (mCNV). It's also approved for cancer treatment and is commonly administered through anti-VEGF injections. \n\",9\n2402,MEDIAN PFS,Median time to progression-free survival,1\n2404,FOUR PATIENTS,Patients who discontinued the treatment,1\n3241,AES,,5\n3857,PROGRESSION-FREE SURVIVAL,,1\n1412,PLATINUM-SENSITIVE EOC,Type of EOC where platinum sensitivity is known,1\n1413,PLATINUM-RESISTANT EOC,Type of EOC where platinum resistance is known,1\n1962,VEGFR-2 MRNA,mRNA expression related to angiogenesis,7\n1966,MI-126,MicroRNA involved in angiogenesis,3\n3258,DEATH,A measure of the death rate in noninfectious myocarditis/pericarditis,4\n5085,U.S. FOOD AND DRUG ADMINISTRATION,\"The U.S. Food and Drug Administration approved bevacizumab for anti-angiogenic therapy in 2004\nThe U.S. Food and Drug Administration approved bevacizumab for anti-angiogenic therapy\",1\n5207,TAT-AT7,\"The **TAT-AT7** entity is being studied as a potential anti-angiogenic drug. It is a peptide known to inhibit angiogenesis, meaning it prevents the formation of new blood vessels.  This peptide has also been investigated for its use in treating glioma, a type of brain tumor. TAT-AT7 is designed for targeted delivery of gene therapies and has shown promise in inhibiting glioma growth. \n\",4\n167,CLINICAL TRIALS,\"**Clinical trials** are an integral part of the development and advancement of anti-angiogenic therapies for patients with **AGC**.  These trials have been instrumental in exploring the potential of **Regorafenib** as a treatment option for various types of cancer, including those affecting the **biliary tract**. Additionally, ongoing research is focused on developing new treatments for **bile duct cancers**, highlighting the crucial role clinical trials play in advancing medical knowledge and improving patient care. \n\",3\n1959,MOTESANIB,Motesanib is a drug used in topical treatment,3\n4324,IA,\"The **IA** group consists of patients who are receiving a specific treatment plan, and also fall under the category of patients receiving IA treatment. \n\",3\n716,PFS,\"The **PFS** (Patient Follow-up Study) is a study focused on patient follow-up success rates and the duration of progression-free survival.  Specifically, it examines the **progression-free survival** in patients with EOC (Epithelial Ovarian Cancer). The study has been associated with terms like \"\"Prolonged progression-free survival\"\" indicating that the PFS is often longer than expected for this type of cancer. \n\",6\n5062,OSCC,\"The **OSCC** (Oral Squamous Cell Carcinoma) is a type of cancer that affects the cells lining the mouth, also known as oral and squamous cell carcinoma. \n\",4\n131,MVD,\"The **MVD** (Microvessel Density) is a measure of the density of blood vessels within a given tissue or sample. It can be derived from specific equations and represents a mathematical value that reflects the amount of microvessels present in a particular area.  It's also used to quantify brain tissue damage, particularly in neurological research. \n\",5\n872,DCE-MRI,\"The **DCE-MRI** technique is a type of imaging used to assess both **angiogenesis** (the formation of new blood vessels) and **tumor tissue**. \n\",3\n1961,VEGF-A MRNA,mRNA expression related to angiogenesis,1\n1963,MI-21,MicroRNA involved in angiogenesis,1\n1964,MI-27A,MicroRNA involved in angiogenesis,1\n1965,MI-31,MicroRNA involved in angiogenesis,1\n1967,MI-184,MicroRNA involved in angiogenesis,1\n1968,MI-204,MicroRNA involved in angiogenesis,1\n1433,PLATINUM-SENSITIVE RELAPSE,A type of cancer that is sensitive to platinum-based chemotherapy,1\n3260,EMBOLIC AND THROMBOTIC EVENTS,The condition is a cardiovascular event,3\n3262,MYOCARDITIS,Inflammation of the heart muscle,3\n3681,REVIEW MANAGER VERSION 5.4.1,,1\n4181,AVASTIN,Drug used to inhibit angiogenesis,1\n4255,PROTAC,A type of molecule used to target proteins,1\n162,BILIARY TRACT CANCERS,Rare cancers of the bile ducts,3\n165,IMMUNE CHECKPOINT INHIBITORS,\"Immune checkpoint inhibitors are a type of cancer treatment that hold potential as a new treatment approach for biliary tract cancers. \n\",3\n885,AUC,Area under the curve,1\n886,PEAK,A peak in a graph,1\n887,WASHIN,A wash-in value in a graph,1\n912,OVERALL SURVIVAL,,3\n3682,ORR,,1\n2403,DISEASE CONTROL RATE,Percentage of patients who achieved disease control,1\n3069,DID NOT RECEIVE ANY TREATMENT,,1\n3065,ANTI-VEGF DRUGS,Type of treatment given to patients,4\n3066,FIRST-LINE TREATMENT,Treatment given as the initial step in a patient's care,1\n3071,NON-SWITCHING MONOTHERAPY,Main treatment regimen for mCNV,1\n4312,ELDERLY PATIENTS,Patients who are elderly and have advanced NSCLC,4\n4313,CHEMO TOLERANCE,,1\n5059,ORAL SQUAMOUS CELL CARCINOMA,A type of cancer,3\n5061,CHEMERIN,\"The **CHEMERIN** protein plays a significant role in both cancer development and angiogenesis.  It has been linked to the development of oral squamous cell carcinoma (OSCC), acting as a contributing factor in its progression. Additionally, CHEMERIN is known to promote angiogenesis, the formation of new blood vessels, which can further contribute to tumor growth and metastasis. \n\",2\n3519,NEUTROPHILS,\"**Neutrophils** are a type of immune cell that plays a crucial role in the inflammatory response. They are highly mobile and infiltrate injured tissue, where they contribute to the body's defense against infection and damage. \n\",3\n5064,MEK/ERK SIGNALING PATHWAY,\"The **MEK/ERK signaling pathway** is a cellular pathway that plays a crucial role in regulating gene expression and protein synthesis. It is involved in various cellular processes, including cell growth, proliferation, differentiation, and survival.  Specifically, this pathway is implicated in the progression of ** OSCC (Oral Squamous Cell Carcinoma)**. \n\",1\n5065,CHEMERN,\"Chemerin, a protein potentially contributing to angiogenesis\",1\n5210,NRP-1,NRP-1 is a receptor for VEGF-A165,1\n785,SPR,Technique used to measure the interaction of molecules,1\n617,VM,\"The **VM** (which stands for **Virus Model**) is a research tool used to study tumor formation.  Specifically, it's often employed in xenograft models, where human cells are transplanted into animal hosts to create tumors that mimic human cancers.  Additionally, the study of viruses and their role in cell formation is an active area of research within the field of oncology.  Furthermore, **VM** has been used to investigate drug resistance in non-small cell lung cancer (NSCLC), a type of aggressive lung cancer. \n\",1\n878,S-ROI,\"Small ROI covering a small solid, highly enhancing focus\",2\n5060,TUMOR ANGIOPNEA,The process of blood vessel formation in tumors,1\n882,V<SUB>E</SUB>,The text describes a variable named V<sub>e</sub> which is likely related to the study of energy,2\n877,L-ROI,Large ROI covering the whole primary lesion,1\n\n\n-----Relationships-----\nhuman_readable_id,source,target,description,combined_degree\n219,NSCLC,ANGIOGENESIS,NSCLC is a disease that can be treated with drugs that inhibit angiogenesis,136\n345,VEGFR-2,VEGF,Expression of VEGFR-2 and VEGF correlate,44\n1459,ADVANCED EGFR-MUTANT NSCLC,OS,Outcome measure in the study,18\n1213,AGIS,COMBINATION THERAPY,Combination therapy,16\n938,OS,MEDIAN OS,The median OS was 14.17 months for patients who received the treatment,15\n1806,NIA,OS,NIA group had shorter OS than IA group,15\n553,OS,PLATINUM-RESISTANT RELAPSE,\"Platinum-resistant relapsed disease is associated with a worse prognosis and lower overall survival rates\nOverall survival in patients with platinum-resistant relapsed EOC is likely to be worse than in patients with platinum-sensitive relapsed EOC\",14\n933,OS,CHEMO,Chemotherapy was associated with better OS than the control group,14\n934,OS,3.60 MONTHS,The OS was 3.60 months in patients who received the treatment,14\n935,OS,14.17 MONTHS,The OS was 14.17 months for patients who received the treatment,14\n936,OS,9.00 MONTHS,\"The OS was 9.00 months for patients who received the treatment\nThe median OS was 9.00 months for patients who received the treatment\",14\n937,OS,73.7%,Most patients (73.7%) received the treatment,14\n939,PATIENTS,COMBINATION THERAPY,Most patients received combination therapy as a fourth and later line of therapy,14\n1210,ICIS,AGIS,\"The **ICIS** (immunotherapy) and **AGIs** (anti-growth factor inhibitors) combination therapy demonstrated a higher incidence of cardiovascular adverse events (AEs).  This combination therapy, known as **combination therapy**, showed a greater risk of cardiovascular AEs. \n\",12\n1453,EGFR-TKIS,ANGIOGENESIS INHIBITORS,Combination therapy for advanced EGFR-mutation NSCLC,12\n1579,NIVOLUMAB MONOTHERAPY,COMBINATION THERAPY,Nivolumab monotherapy is a part of combination therapy,12\n548,EOC,BEVACIZUMAB,Bevacizumab is a treatment for EOC,11\n941,COMBINATION THERAPY,MEDIAN PFS,Median PFS for patients receiving combination therapy,11\n943,COMBINATION THERAPY,FOUR PATIENTS,Four patients discontinued combination therapy due to adverse events,11\n1212,ICIS,AES,Cardiovascular adverse events,11\n1582,COMBINATION THERAPY,PROGRESSION-FREE SURVIVAL,The combination therapy group had better progression-free survival than the nivolumab monotherapy group,11\n549,BEVACIZUMAB,PLATINUM-SENSITIVE EOC,Bevacizumab is used to treat platinum-sensitive EOC,10\n550,BEVACIZUMAB,PLATINUM-RESISTANT EOC,Bevacizumab is used to treat platinum-resistant EOC,10\n745,VEGFR-2 MRNA,MI-126,MicroRNA-126 is involved in the regulation of VEGFR-2 expression,10\n1219,ICIS,DEATH,Combination therapy with ICIs showed a lower frequency of death,10\n2210,U.S. FOOD AND DRUG ADMINISTRATION,BEVACIZUMAB,\"Bevacizumab was approved by the U.S. Food and Drug Administration as an anti-angiogenic therapy in 2004\nThe U.S. Food and Drug Administration approved bevacizumab for anti-angiogenic therapy in 2004\",10\n2303,TAT-AT7,VEGFR-2,\"The **TAT-AT7** molecule is a compound that competitively binds to the **VEGFR-2** receptor. This binding action prevents the binding of **VEGF-A165**, a signaling protein, to the **VEGFR-2** receptor.  Therefore, TAT-AT7 targets the **VEGFR-2** receptor. \n\",10\n54,ANGIOGENESIS INHIBITORS,CLINICAL TRIALS,Clinical trials are evaluating combination strategies with angiogenesis inhibitors,9\n748,MOTESANIB,VEGFR-2,Motesanib statistically significantly suppressed the VEGFR-2 mRNA level compared with other treatment doses,9\n1803,IA,PFS,IA group had longer PFS than NIA group,9\n2204,OSCC,MVD,Combination of MVD and OSCC is a more effective factor in predicting survival time,9\n344,MVD,DCE-MRI,DCE-MRI parameters correlate with microvessel density,8\n741,VEGF-A MRNA,VEGFR-2 MRNA,Expression levels of VEGFR-2 and VEGF-A are related to angiogenesis,8\n742,VEGFR-2 MRNA,MI-21,MicroRNA-21 is involved in the regulation of VEGFR-2 expression,8\n743,VEGFR-2 MRNA,MI-27A,MicroRNA-27a is involved in the regulation of VEGFR-2 expression,8\n744,VEGFR-2 MRNA,MI-31,MicroRNA-31 is involved in the regulation of VEGFR-2 expression,8\n746,VEGFR-2 MRNA,MI-184,MicroRNA-184 is involved in the regulation of VEGFR-2 expression,8\n747,VEGFR-2 MRNA,MI-204,MicroRNA-204 is involved in the regulation of VEGFR-2 expression,8\n554,PFS,PLATINUM-SENSITIVE RELAPSE,\"Platinum-sensitive relapsed disease is associated with a better prognosis and higher progression-free survival rates\nProgression-free survival in patients with platinum-sensitive relapsed EOC is likely to be better than in patients with platinum-resistant relapsed EOC\",7\n1223,EMBOLIC AND THROMBOTIC EVENTS,DEATH,Combination therapy with ICIs and AGIs increased the risk of death,7\n1224,MYOCARDITIS,DEATH,Combination therapy with AGIs decreased the frequency of death,7\n1455,EGFR-TKIS,REVIEW MANAGER VERSION 5.4.1,Software used for data analysis,7\n1726,AVASTIN,ANGIOGENESIS INHIBITORS,Tivozanib,7\n1774,PROTAC,ANGIOGENESIS INHIBITORS,PROTACs could be used to overcome clinical resistance of traditional angiogenesis inhibitors,7\n50,BILIARY TRACT CANCERS,IMMUNE CHECKPOINT INHIBITORS,Potential to change first-line treatment approach,6\n52,BILIARY TRACT CANCERS,CLINICAL TRIALS,Ongoing research and testing of new treatments for biliary tract cancers,6\n53,IMMUNE CHECKPOINT INHIBITORS,CLINICAL TRIALS,Clinical trials are evaluating combination strategies with immunotherapy and other anticancer agents,6\n341,MVD,AUC,\"Microvessel density correlates with AUC, Peak and WashIn values\",6\n342,MVD,PEAK,Microvessel density correlates with peak in a graph,6\n343,MVD,WASHIN,Microvessel density correlates with wash-in value in a graph,6\n365,CERVICAL CANCER,OVERALL SURVIVAL,Risk factors for the overall survival of cervical cancer patients were identified using data from The Cancer Genome Atlas,6\n1460,ADVANCED EGFR-MUTANT NSCLC,ORR,Outcome measure in the study,6\n940,PATIENTS,DISEASE CONTROL RATE,Disease control rate of 92.1% was achieved in the study,5\n1138,PATIENTS,DID NOT RECEIVE ANY TREATMENT,77% of patients did not receive any treatment in their second year of treatment regardless of drugs,5\n1140,ANTI-VEGF DRUGS,FIRST-LINE TREATMENT,Anti-VEGF drugs were the first line of treatment for patients,5\n1143,ANTI-VEGF DRUGS,NON-SWITCHING MONOTHERAPY,Anti-VEGF drugs are used as the main treatment regimen for mCNV,5\n1800,ELDERLY PATIENTS,CHEMO TOLERANCE,Elderly patients have poor chemotherapy tolerance,5\n2202,ORAL SQUAMOUS CELL CARCINOMA,CHEMERIN,Chemerin is a protein that plays a role in OSCC development,5\n2203,NEUTROPHILS,CHEMERIN,Neutrophils are involved in the regulation of Chemerin expression,5\n2206,OSCC,MEK/ERK SIGNALING PATHWAY,The MEK/ERK pathway is involved in the progression of OSCC,5\n2207,OSCC,CHEMERN,Chemerin potentially contributes to the progression and metastasis of OSCC,5\n2304,TAT-AT7,NRP-1,TAT-AT7 competitively binds to NRP-1 and prevents VEGF-A165 binding,5\n2306,TAT-AT7,SPR,TAT-AT7 was proven to competitively bind to VEGFR-2 and NRP-1 using SPR assay,5\n220,NSCLC,VM,NSCLC is a disease that can be treated with drugs that inhibit VM,4\n338,S-ROI,EOC,S-ROI is used to analyze data from the EOC,4\n2200,ORAL SQUAMOUS CELL CARCINOMA,TUMOR ANGIOPNEA,\"OSCC contributes to tumor angiogenesis\nChemerin overexpression is associated with increased neutrophil infiltration in OSCC\nOSCC can lead to increased angiogenesis\",4\n339,V<SUB>E</SUB>,L-ROI,The mathematical value V<sub>e</sub> is related to the L-ROI parameter,3\n\n\nThe report should include the following sections:\n\n- TITLE: community's name that represents its key entities - title should be short but specific. When possible, include representative named entities in the title.\n- SUMMARY: An executive summary of the community's overall structure, how its entities are related to each other, and significant information associated with its entities.\n- IMPACT SEVERITY RATING: a float score between 0-10 that represents the severity of IMPACT posed by entities within the community.  IMPACT is the scored importance of a community.\n- RATING EXPLANATION: Give a single sentence explanation of the IMPACT severity rating.\n- DETAILED FINDINGS: A list of 5-10 key insights about the community. Each insight should have a short summary followed by multiple paragraphs of explanatory text grounded according to the grounding rules below. Be comprehensive.\n\nReturn output as a well-formed JSON-formatted string with the following format:\n    {{\n        \"title\": <report_title>,\n        \"summary\": <executive_summary>,\n        \"rating\": <impact_severity_rating>,\n        \"rating_explanation\": <rating_explanation>,\n        \"findings\": [\n            {{\n                \"summary\":<insight_1_summary>,\n                \"explanation\": <insight_1_explanation>\n            }},\n            {{\n                \"summary\":<insight_2_summary>,\n                \"explanation\": <insight_2_explanation>\n            }}\n        ]\n    }}\n\n# Grounding Rules\n\nPoints supported by data should list their data references as follows:\n\n\"This is an example sentence supported by multiple data references [Data: <dataset name> (record ids); <dataset name> (record ids)].\"\n\nDo not list more than 5 record ids in a single reference. Instead, list the top 5 most relevant record ids and add \"+more\" to indicate that there are more.\n\nFor example:\n\"Person X is the owner of Company Y and subject to many allegations of wrongdoing [Data: Reports (1), Entities (5, 7); Relationships (23); Claims (7, 2, 34, 64, 46, +more)].\"\n\nwhere 1, 5, 7, 23, 2, 34, 46, and 64 represent the id (not the index) of the relevant data record.\n\nDo not include information where the supporting evidence for it is not provided.\n\nOutput:", "role": "user"}], "parameters": {"model": "gemma2:2b", "frequency_penalty": 0.0, "max_tokens": 2000, "n": 1, "presence_penalty": 0.0, "temperature": 0.0, "top_p": 1.0, "response_format": {"type": "json_object"}}}, "key": "chat_create_community_report_81fbf1603452ce80993d3d3ec6090c63b0d7d3877138f8f193ee148002ec3947_v2"}